The BCR-ABL fusion protein in chronic myelogenous leukemia (CML) has been shown to be immunogenic, with the induction of specific T cells capable of lysing tumor cells expressing the BCR-ABL protein. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.